— HUTCHMED to present in person and via online webinar on Friday, October 31 —
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 — HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) announced today that it will host a Research & Development update in Shanghai, China, and via webcast on Friday, October 31, 2025.
During the event, Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED, will offer insights into the company’s R&D strategy and vision. This will include an overview of the company’s Antibody Targeted Therapy Conjugates platform, featuring its lead candidate HMPL-A251, and updates on late-stage pipeline development.
The in-person event will be held in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Chinese (Putonghua). A live webcast will be available at the same time. Attendance at the in-person event is by invitation only.
An English webcast will be held from 8:00 p.m. HKT / 8:00 a.m. EDT / 12:00 noon GMT on Friday, October 31, lasting approximately one hour.
Both webcasts will be available live on the company website. A replay will also be available on the website soon after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative biopharmaceutical company in the commercial stage. It is dedicated to discovering, developing, and commercializing targeted therapies and immunotherapies globally for treating cancer and immunological diseases. Since its beginning, it has concentrated on moving drug candidates from internal discovery to patients globally. Its first three medications are marketed in China, with the first also approved worldwide, including in the US, Europe, and Japan. For more information, please visit or follow us on .
Forward-Looking Statements
This press release contains forward-looking statements as defined in the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties. Investors should not rely excessively on these forward-looking statements, which are relevant only as of this date. For a more detailed discussion of these risks, please refer to HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited, and AIM. HUTCHMED is not obligated to update or revise the information in this press release due to new information, future events, or other factors.
CONTACTS
| Investor Enquiries | +852 2121 8200 / |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
“`